Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry

Epilepsy Behav. 2003 Jun;4(3):310-7. doi: 10.1016/s1525-5050(03)00110-0.


The objective of this study was to assess the safety of gabapentin (Neurontin) exposure in human pregnancy. Prospective and retrospective data concerning 51 fetuses, including 3 twin gestations, were collected from 39 women with epilepsy and other disorders exposed to gabapentin during pregnancy. Data were collected and evaluated about the 44 live births, including maternal demographics, diagnosis, treatment and complications, and fetal complications and outcomes. The results of this study showed that the rates of maternal complication, cesarean section, miscarriage, low birth weight, and malformation were less than or similar to those seen in the general population or among women with epilepsy. Gabapentin exposure during pregnancy did not lead to an increased risk for adverse maternal and fetal events in this study. However, because of the small number of patients examined in this study, additional data from more pregnancies and outcomes are needed.

MeSH terms

  • Acetates / administration & dosage
  • Acetates / therapeutic use*
  • Adult
  • Amines*
  • Anticonvulsants / administration & dosage
  • Anticonvulsants / therapeutic use*
  • Cyclohexanecarboxylic Acids*
  • Epilepsy / drug therapy*
  • Female
  • Gabapentin
  • Humans
  • Pregnancy
  • Pregnancy Complications / epidemiology
  • Pregnancy Outcome
  • Prospective Studies
  • Registries*
  • Retrospective Studies
  • Surveys and Questionnaires
  • gamma-Aminobutyric Acid*


  • Acetates
  • Amines
  • Anticonvulsants
  • Cyclohexanecarboxylic Acids
  • gamma-Aminobutyric Acid
  • Gabapentin